Literature DB >> 6083405

Theoretical bases for vascular selectivity of Ca2+ antagonists.

C Cauvin, S Lukeman, J Cameron, O Hwang, K Meisheri, H Yamamoto, C van Breemen.   

Abstract

The purpose of these studies was to characterize mechanisms of activation of vascular tissues in order to clarify possible theoretical bases for Ca2+-antagonist (CAt) selectivity. Activation of rabbit aorta, mesenteric artery, and mesenteric resistance vessels by agonists and depolarizing potassium (K+) solution, and inhibition by CAts were studied by measurement of contractions, 45Ca fluxes, and membrane potentials (via intracellular electrodes). We found that the CAts studied (D-600, diltiazem, and nisoldipine) inhibited K+-induced Ca2+ influx and contractions in a closely correlated manner, suggesting inhibition of Ca2+ entry as their primary, if not sole, mechanism of action. Diltiazem and nisoldipine had no effect on intracellular Ca2+ release or on the contractile protein system. The following evidence was obtained to support the tenet that norepinephrine (NE) and 80 mM K+ open two distinct Ca2+ channels, one receptor-operated (ROC) and the other potential-operated (POC): (a) NE activated the rabbit aorta without eliciting a change in membrane potential; (b) NE activation of the rabbit mesenteric resistance vessels was accompanied by membrane depolarization, but this depolarization was blocked by 10(-5) M diltiazem, whereas that induced by 80 mM K+ was not; (c) 45Ca influx stimulated by 80 mM K+ and that stimulated by a maximal [NE] were additive when the two agents were administered together in the aorta and the resistance vessels; (d) the Ca2+-channel agonist Bay K8644 opens the POC but not the ROC in rabbit aorta, as it is capable of stimulating Ca2+ influx in addition to 10(-5) M NE, but not to 80 mM K+; (e) the CAts show selective inhibition of the POC over the ROC in the aorta, whereas diltiazem preferentially inhibits the ROC in the resistance vessels; and (f) alpha adrenoreceptor occupation, phosphodiesterase inhibition, or dibutyryl cyclic AMP selectively inhibits the POC over the ROC in the aorta.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083405     DOI: 10.1097/00005344-198406004-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  The pharmacological properties of K+ currents from rabbit isolated aortic smooth muscle cells.

Authors:  F C Halliday; P I Aaronson; A M Evans; A M Gurney
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Differences between the effects of cromakalim and nifedipine on agonist-induced responses in rabbit aorta.

Authors:  K M Bray; A H Weston; S Duty; D T Newgreen; J Longmore; G Edwards; T J Brown
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  The mechanism of phenylephrine-mediated [Ca(2+)](i) oscillations underlying tonic contraction in the rabbit inferior vena cava.

Authors:  C H Lee; D Poburko; P Sahota; J Sandhu; D O Ruehlmann; C van Breemen
Journal:  J Physiol       Date:  2001-08-01       Impact factor: 5.182

4.  Effects of calcium entry blocking agents on 5-hydroxytryptamine- and noradrenaline-induced contractions of rat isolated jugular vein and aorta.

Authors:  M A Gouw; B Wilffert; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

5.  Pharmacological properties of alpha 1-adrenoceptor-mediated vasoconstrictions in dog and monkey lingual arteries: evidence for subtypes of alpha 1-adrenoceptors.

Authors:  R Skrbic; S Chiba
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

6.  Evidence for the presence of regional differences in the calcium antagonist receptors in lower urinary tract smooth muscle.

Authors:  J Latifpour; M Yoshida; R M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

Review 7.  The pharmacology of nisoldipine.

Authors:  A Knorr
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 8.  How do calcium antagonists differ in clinical practice?

Authors:  R Ferrari; F Cucchini; R Bolognesi; T Bachetti; A Boraso; P Bernocchi; G Gaia; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

9.  Effects of calcium channel blockade in canine saphenous veins after storage at -190 degrees C.

Authors:  A B Ebeigbe; E Müller-Schweinitzer; A Vogel
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

10.  Anti-vasoconstrictor effects of the K+ channel opener cromakalim on the rabbit aorta--comparison with the calcium antagonist isradipine.

Authors:  N S Cook; S W Weir; M C Danzeisen
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.